Protheragen Launches Advanced Drug Delivery Services for Global Pharmaceutical and Biomedical Innovators

Protheragen is proud to announce an expanded portfolio of specialized drug delivery system services designed to address critical challenges in modern pharmacology. By offering integrated solutions including hydrogel delivery platforms, advanced microneedle development, and lyophilized flash-release formulations, the company empowers pharmaceutical researchers to overcome obstacles such as low bioavailability, unstable efficacy, and limited targeting capabilities.

The company’s hydrogel technology leverages biocompatible 3D polymer networks to facilitate stimulus-responsive, sustained drug release, while its comprehensive microneedle services provide a minimally invasive alternative for transdermal delivery. These solutions are meticulously engineered to bypass gastrointestinal metabolism, thereby enhancing therapeutic indices and significantly improving patient compliance across various clinical applications including ocular, injectable, and topical treatments.

To ensure seamless transition from research to commercialization, Protheragen provides a holistic, one-stop development workflow. From initial formulation design and material selection to rigorous quality testing and scale-up, these services ensure that every product meets stringent global regulatory standards. By accelerating the transformation of novel therapeutic candidates, Protheragen remains at the forefront of driving innovation and improving the overall value of next-generation pharmaceutical products.